High throughput screening of particle conditioning operations: II. Evaluation of scale-up heuristics with prokaryotically expressed polysaccharide vaccines.
Multivalent polysaccharide conjugate vaccines are typically comprised of several different polysaccharides produced with distinct and complex production processes. Particle conditioning steps, such as precipitation and flocculation, may be used to aid the recovery and purification of such microbial vaccine products. An ultra scale-down approach to purify vaccine polysaccharides at the micro-scale would greatly enhance productivity, robustness, and speed the development of novel conjugate vaccines. In part one of this series, we described a modular and high throughput approach to develop particle conditioning processes (HTPC) for biologicals that combines flocculation, solids removal, and streamlined analytics. In this second part of the series, we applied HTPC to industrially relevant feedstreams comprised of capsular polysaccharides (CPS) from several bacterial species. The scalability of HTPC was evaluated between 0.8 mL and 13 L scales, with several different scaling methodologies examined. Clarification, polysaccharide yield, impurity clearance, and product quality achieved with HTPC were reproducible and comparable with larger scales. Particle sizing was the response with greatest sensitivity to differences in processing scale and enabled the identification of useful scaling rules. Scaling with constant impeller tip speed or power per volume in the impeller swept zone offered the most accurate scale up, with evidence that time integration of these values provided the optimal basis for scaling. The capability to develop a process at the micro-scale combined with evidence-based scaling metrics provide a significant advance for purification process development of vaccine processes. The USD system offers similar opportunities for HTPC of proteins and other complex biological molecules.
The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Bernard Katz Building, Gordon Street, London, WC1E 7JE, UK.|Pfizer Bioprocess R&D, Andover, Massachusetts.
Aaron
A
Noyes
Pfizer Bioprocess R&D, Chesterfield, Missouri.
Ben
B
Huffman
Pfizer Bioprocess R&D, Chesterfield, Missouri.
Alex
A
Berrill
Pfizer Vaccine Research Unit, Pearl River, New York.
Nick
N
Merchant
Pfizer Bioprocess R&D, Andover, Massachusetts.
Ranga
R
Godavarti
The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Bernard Katz Building, Gordon Street, London, WC1E 7JE, UK.
Nigel
N
Titchener-Hooker
Pfizer Bioprocess R&D, Andover, Massachusetts.
Jonathan
J
Coffman
Pfizer Bioprocess R&D, Chesterfield, Missouri.
Khurram
K
Sunasara
The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Bernard Katz Building, Gordon Street, London, WC1E 7JE, UK. ucbetkm@ucl.ac.uk.
Tarit
T
Mukhopadhyay
D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification*; D001688:Biological Products / Q000276:immunology* / Q000302:isolation & purification*; D019149:Bioreactors / Q000382:microbiology; D011135:Polysaccharides, Bacterial / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification*; D013678:Technology, Pharmaceutical / Q000379:methods*
D001428:Bacterial Vaccines; D001688:Biological Products; D011135:Polysaccharides, Bacterial
DOE; MALS; QbD; capsular polysaccharide; clarification; flocculation; high throughput process development; particle conditioning; precipitation; purity; scalability; screening; ultra scale-down; vaccine; windows of operation; yield